FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, Feb 13, 2020

Coronavirus Patients in China to be Treated with High-Dose Vitamin C

by Andrew W. Saul, Editor

(OMNS February 13, 2020) Breaking news: China is conducting a clinical trial of 24,000 mg/day of intravenous vitamin C to treat patients with coronavirus and severe respiratory complications. Participants will receive IV vitamin C for 7 days straight at Zhongnan Hospital of Wuhan University. Honor and thanks are due to Zhiyong Peng, MD, for making this happen. He is chief physician and professor at the hospital, which is close to ground zero for coronavirus. This important study was filed and announced yesterday and details may be confirmed at https://clinicaltrials.gov/ct2/show/NCT04264533

At Zhongnan Hospital in Wuhan, China, 24,000 mg of vitamin C will be administered to coronavirus patients, intravenously, each day for 7 days.

To fight a dangerous virus for which there is no existing medical treatment, you must rely on your own immune system. It is well established, in every nutrition textbook ever written, that you need vitamin C to make your immune system work well, or to even work at all. Inadequate vitamin C intake is a worldwide problem that can be immediately and economically fixed. With even modest amounts of supplemental vitamin C, deaths will decrease. In one study, a mere 200 mg of vitamin C/day resulted in an 80% decrease in deaths among severely ill, hospitalized respiratory disease patients. [Hunt C et al. Int J Vitam Nutr Res 1994;64:212-19.] http://orthomolecular.org/resources/omns/v16n09.shtml

Another recent study used this same low 200 mg dose for infants and children under five years of age, with severe pneumonia. The authors concluded that "Vitamin C is effective in reducing duration of severe pneumonia in children less than five years of age. Oxygen saturation was improved in less than one day." [Khan IM et al. J Rawalpindi Med Coll (JRMC); 2014;18(1):55-57 http://www.journalrmc.com/volumes/1405749894.pdf ]

A lack of vitamin C has been long known, literally for decades, to increase susceptibility to viruses. http://orthomolecular.org/resources/omns/v16n06.shtml It is one thing to be sick from a virus and another thing entirely to die from a viral-instigated disease. The greatest danger with coronavirus is escalation to pneumonia. For this, much higher doses of vitamin C are indicated, preferably by IV.

How to administer high-dose intravenous vitamin C in hospital, Chinese language edition, is now posted for free access at http://www.doctoryourself.com/Coronavirus_Chinese_IV_C_Protocol.pdf This information is now being publicized all over Asia. Just because it is not on the American news channels doesn't mean it's not happening. It is. This is real news. The fake news is the media's neglect in not reporting it. And here is the protocol in English, to make reporting all the easier: http://orthomolecular.org/resources/omns/v16n07.shtml

(OMNS Editor-in-Chief Andrew W. Saul is a member of the Medical and Scientific Advisory Board to the International Intravenous Vitamin C China Epidemic Medical Support Team. Its director is Richard Z. Cheng, MD, PhD; associate director is Hong Zhang, PhD. Other team members that American readers will recognize include Jeanne Drisko, MD (Professor, University of Kansas Medical School); Thomas Levy, MD, JD; and Atsuo Yanagisawa, MD, PhD. (Professor, Kyorin University, Tokyo).

Intravenous Vitamin C Protocol in English: http://orthomolecular.org/resources/omns/v16n07.shtml

IVC Protocol in Chinese: http://www.doctoryourself.com/Coronavirus_Chinese_IV_C_Protocol.pdf

Nutritional Medicine is Orthomolecular Medicine

Orthomolecular medicine uses safe, effective nutritional therapy to fight illness. For more information: http://www.orthomolecular.org

Find a Doctor

To locate an orthomolecular physician near you: http://orthomolecular.org/resources/omns/v06n09.shtml

The peer-reviewed Orthomolecular Medicine News Service is a non-profit and non-commercial informational resource.

Editorial Review Board:

Ilyès Baghli, M.D. (Algeria)
Ian Brighthope, M.D. (Australia)
Richard Cheng, M.D., Ph.D. (USA)
Prof. Gilbert Henri Crussol (Spain)
Carolyn Dean, M.D., N.D. (USA)
Damien Downing, M.D. (United Kingdom)
Michael Ellis, M.D. (Australia)
Martin P. Gallagher, M.D., D.C. (USA)
Michael J. Gonzalez, N.M.D., D.Sc., Ph.D. (Puerto Rico)
William B. Grant, Ph.D. (USA)
Tonya S. Heyman, M.D. (USA)
Suzanne Humphries, M.D. (USA)
Ron Hunninghake, M.D. (USA)
Michael Janson, M.D. (USA)
Robert E. Jenkins, D.C. (USA)
Bo H. Jonsson, M.D., Ph.D. (Sweden)
Jeffrey J. Kotulski, D.O. (USA)
Peter H. Lauda, M.D. (Austria)
Thomas Levy, M.D., J.D. (USA)
Homer Lim, M.D. (Philippines)
Stuart Lindsey, Pharm.D. (USA)
Victor A. Marcial-Vega, M.D. (Puerto Rico)
Charles C. Mary, Jr., M.D. (USA)
Mignonne Mary, M.D. (USA)
Jun Matsuyama, M.D., Ph.D. (Japan)
Dave McCarthy, M.D. (USA)
Joseph Mercola, D.O. (USA)
Jorge R. Miranda-Massari, Pharm.D. (Puerto Rico)
Karin Munsterhjelm-Ahumada, M.D. (Finland)
Tahar Naili, M.D. (Algeria)
W. Todd Penberthy, Ph.D. (USA)
Dag Viljen Poleszynski, Ph.D. (Norway)
Jeffrey A. Ruterbusch, D.O. (USA)
Gert E. Schuitemaker, Ph.D. (Netherlands)
Thomas L. Taxman, M.D. (USA)
Jagan Nathan Vamanan, M.D. (India)
Garry Vickar, MD (USA)
Ken Walker, M.D. (Canada)
Anne Zauderer, D.C. (USA)

Andrew W. Saul, Ph.D. (USA), Editor-In-Chief
Editor, Japanese Edition: Atsuo Yanagisawa, M.D., Ph.D. (Japan)
Robert G. Smith, Ph.D. (USA), Associate Editor
Helen Saul Case, M.S. (USA), Assistant Editor
Michael S. Stewart, B.Sc.C.S. (USA), Technology Editor
Jason M. Saul, JD (USA), Legal Consultant

Comments and media contact: drsaul@doctoryourself.com OMNS welcomes but is unable to respond to individual reader emails. Reader comments become the property of OMNS and may or may not be used for publication.

To Subscribe at no charge: http://www.orthomolecular.org/subscribe.html

To Unsubscribe from this list: http://www.orthomolecular.org/unsubscribe.html